Aurinia Pharmaceuticals Inc
F:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
F:IKAP
|
CA |
|
Clean Energy Fuels Corp
LSE:0I04
|
US |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals is a biopharmaceutical company focused on medicines for autoimmune diseases, especially kidney complications tied to lupus. Its main product is LUPKYNIS, a prescription drug used to treat adults with active lupus nephritis, a serious form of kidney inflammation caused by lupus. The company’s work is centered on developing, selling, and supporting this medicine in the U.S. and other markets where it has rights. The company makes money mainly by selling its drug through the healthcare system. Its customers are not patients directly, but doctors, hospitals, specialty pharmacies, and insurers that decide whether and how the treatment is used and paid for. Aurinia also depends on medical specialists who prescribe the drug and on reimbursement from payers, since this is a branded prescription medicine. What makes Aurinia’s business model different is that it is a single-product, disease-focused drug company built around a specific kidney condition rather than a broad portfolio. That means its success depends heavily on how well one medicine is adopted, prescribed, and covered. For beginner investors, it is best understood as a specialty pharma company trying to turn a targeted treatment for lupus nephritis into a durable commercial franchise.
Aurinia Pharmaceuticals is a biopharmaceutical company focused on medicines for autoimmune diseases, especially kidney complications tied to lupus. Its main product is LUPKYNIS, a prescription drug used to treat adults with active lupus nephritis, a serious form of kidney inflammation caused by lupus. The company’s work is centered on developing, selling, and supporting this medicine in the U.S. and other markets where it has rights.
The company makes money mainly by selling its drug through the healthcare system. Its customers are not patients directly, but doctors, hospitals, specialty pharmacies, and insurers that decide whether and how the treatment is used and paid for. Aurinia also depends on medical specialists who prescribe the drug and on reimbursement from payers, since this is a branded prescription medicine.
What makes Aurinia’s business model different is that it is a single-product, disease-focused drug company built around a specific kidney condition rather than a broad portfolio. That means its success depends heavily on how well one medicine is adopted, prescribed, and covered. For beginner investors, it is best understood as a specialty pharma company trying to turn a targeted treatment for lupus nephritis into a durable commercial franchise.
LUPKYNIS Growth: LUPKYNIS sales grew 25% year-over-year in 2025, with strong momentum continuing across both patient adherence and prescriber base.
Revenue & Profit Surge: Total Q4 2025 revenue reached $77.1 million (up 29%), and full-year revenue was $283.1 million (up 20%). Net income soared due to a large tax benefit.
2026 Guidance: Management guided for 2026 total revenue of $315–325 million and LUPKYNIS product sales of $305–315 million, reflecting 11–16% expected growth.
Tax Benefit Impact: A $175.1 million Q4 tax benefit from the release of a valuation allowance led to a significant net income increase.
Aritinercept Pipeline: Aurinia is advancing aritinercept, a novel biologic for autoimmune diseases, with new studies underway and more updates expected in Q2 2026.
Competitive Landscape: New competition like Gazyva has not yet impacted LUPKYNIS sales, and management believes the market is still expanding.
Share Buybacks: The company repurchased 12.2 million shares in 2025, reducing diluted shares outstanding.
